Browsing Tag
Natera
3 posts
Genentech secures first ctDNA MRD-guided therapy approval for Tecentriq in MIBC
A cancer drug win is only half the story. Roche and Natera are testing whether ctDNA can decide who truly needs treatment.
Guardant Health (NASDAQ: GH) surges 27% after blowout quarter: What it means for diagnostics investors
Find out how Guardant Health’s strong Q3 performance triggered a diagnostics rally — and what it means for investors in the early-detection boom.
Inocras launches MRDVision with ppm-level sensitivity, setting new standard in cancer recurrence detection
Inocras launches MRDVision with ppm-level ctDNA sensitivity, setting a new MRD testing standard—discover how it could transform cancer monitoring today.